Replimune Announces Priority Review for Melanoma Treatment (NASDAQ:REPL) -

RepliMoney Group (Nasdaq: Reply) announced that the US Food and Drug Administration has accepted a biosimilar license application for RP1 in combination with nivolumab for patients with advanced melanoma.

The FDA granted BLA priority review to the prescription drug user

Contents

1 Related posts:
2 Japanese bond returns are 16 years old
3 China says it is ready to fight any kind of war with the United States "to the end" with the ease of...
4 American solar energy companies rely on Xinjiang materials, where forced work is outsider

Japanese bond returns are 16 years old

China says it is ready to fight any kind of war with the United States "to the end" with the ease of...

American solar energy companies rely on Xinjiang materials, where forced work is outsider

Say Job City

Say Job City in Pakistan for today latest jobs opportunities in private and Govt departments. View all new Government careers collected from daily. sayjobcity.com

sayjobcity.com